This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies
March 11-14, 2024 | Part of BPI West
Town and Country ResortSan Diego, CA

James Chung, M.D., PhD.
Chief Medical Officer at Kyverna Therapeutics


James Chung, MD, PhD is the Chief Medical Officer of Kyverna Therapeutics. Prior to Kyverna Dr. Chung was at Amgen where he began in Early Development and served as the Inflammation Therapeutic Area Head. He also worked in late-stage development as the Global Development Leader for Enbrel and as the Inflammation head for the US and Global Medical Organizations. Prior to Amgen he worked in early development, Inflammation, at Pfizer. Dr. Chung obtained his MD and PhD in immunology at the University of Pennsylvania where he also completed his residency in Internal Medicine and fellowship in Rheumatology.

Agenda Sessions

  • Development of Anti-CD19 CAR T-Cell Therapy for Autoimmune Diseases


Speakers at this event